Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention

  • The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints
  • Aimovig showed superior tolerability and efficacy against topiramate and provided a significant reduction in monthly migraine days (MMDs)
  • Aimovig is the most prescribed anti-calcitonin gene-related peptide pathway (anti-CGRP) …
/by